RMAM
CASC

Raab & Moskowitz Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-250
Closed -$3K – 438
2014
Q4 		$3K Buy
+250
New +$2.71K ﹤0.01% 432

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Raab & Moskowitz Asset Management's CASC Position: Q1 2015 in Review

Raab & Moskowitz Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2015, closing a stake of 250 shares — an estimated $3K sold.

Raab & Moskowitz Asset Management first reported a position in CASC in Q4 2014 and held it in 1 quarter. The position peaked at $3K in Q4 2014. 90 funds tracked by Wall St. Rank hold CASC as of Q1 2015.

  • Raab & Moskowitz Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 250 Cascadian Therapeutics, Inc. shares in Q1 2015, an estimated $3K.
  • Raab & Moskowitz Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Raab & Moskowitz Asset Management's Cascadian Therapeutics, Inc. position peaked at $3K in Q4 2014.
  • 90 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2015.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2015, filed 12 May 2015.